Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor?

Juan C. Gutierrez, Michael C. Cheung, Ying Zhuge, Leonidas G. Koniaris, Juan E Sola

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: To determine prognostic significance of hospital surgical volume and Children's Oncology Group (COG) membership on neuroblastoma (NBL) and Wilms tumor (WT) survival. Methods: The Florida Cancer Data System was queried from 1981 to 2004. Results: Of 869 NBL patients, 463 were treated at COG/HVC, 246 at COG/LVC, and 160 at non-COG/LVC. COG hospitals treated a larger proportion of patients <1 year of age (P = 0.002) and relatively more patients with adrenal and mediastinal tumors (P = 0.005). COG centers more frequently administered chemotherapy (72% vs. 51%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (70.6%, 67.7%) and COG/LVC (75.8%, 72.6%) than non-COG/LVC (59.5%, 54.4%, P < 0.05). Of 790 WT patients, 395 were treated at COG/HVC, 210 at COG/LVC, and 185 at non-COG/LVC. COG hospitals treated younger patients and lower staged tumors (P < 0.05). COG centers more frequently administered chemotherapy (88% vs. 59%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (91.3%, 89.9%) and COG/LVC (96.7%, 94.7%) than non-COG/LVC (82.4%, 81.7%, P < 0.05). Multivariate analysis demonstrated WT patients treated at non-COG hospitals, but not NBL patients, had worse survival (HR 3.107, P = 0.01). Conclusion: Children treated at COG hospitals had higher overall use of chemotherapy. This translated into a significantly improved survival benefit for WT. Pediatr Blood Cancer.

Original languageEnglish
Pages (from-to)621-628
Number of pages8
JournalPediatric Blood and Cancer
Volume55
Issue number4
DOIs
StatePublished - Oct 1 2010

Fingerprint

Wilms Tumor
Neuroblastoma
Survival
Drug Therapy
Neoplasms
Survival Rate
Information Systems

Keywords

  • FCDS
  • Neuroblastoma
  • Pediatric tumors
  • Volume-outcomes
  • Wilms tumor

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor? / Gutierrez, Juan C.; Cheung, Michael C.; Zhuge, Ying; Koniaris, Leonidas G.; Sola, Juan E.

In: Pediatric Blood and Cancer, Vol. 55, No. 4, 01.10.2010, p. 621-628.

Research output: Contribution to journalArticle

Gutierrez, Juan C. ; Cheung, Michael C. ; Zhuge, Ying ; Koniaris, Leonidas G. ; Sola, Juan E. / Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor?. In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 4. pp. 621-628.
@article{468cd5d12f854b95be483e2e4d585c0c,
title = "Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor?",
abstract = "Purpose: To determine prognostic significance of hospital surgical volume and Children's Oncology Group (COG) membership on neuroblastoma (NBL) and Wilms tumor (WT) survival. Methods: The Florida Cancer Data System was queried from 1981 to 2004. Results: Of 869 NBL patients, 463 were treated at COG/HVC, 246 at COG/LVC, and 160 at non-COG/LVC. COG hospitals treated a larger proportion of patients <1 year of age (P = 0.002) and relatively more patients with adrenal and mediastinal tumors (P = 0.005). COG centers more frequently administered chemotherapy (72{\%} vs. 51{\%}, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (70.6{\%}, 67.7{\%}) and COG/LVC (75.8{\%}, 72.6{\%}) than non-COG/LVC (59.5{\%}, 54.4{\%}, P < 0.05). Of 790 WT patients, 395 were treated at COG/HVC, 210 at COG/LVC, and 185 at non-COG/LVC. COG hospitals treated younger patients and lower staged tumors (P < 0.05). COG centers more frequently administered chemotherapy (88{\%} vs. 59{\%}, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (91.3{\%}, 89.9{\%}) and COG/LVC (96.7{\%}, 94.7{\%}) than non-COG/LVC (82.4{\%}, 81.7{\%}, P < 0.05). Multivariate analysis demonstrated WT patients treated at non-COG hospitals, but not NBL patients, had worse survival (HR 3.107, P = 0.01). Conclusion: Children treated at COG hospitals had higher overall use of chemotherapy. This translated into a significantly improved survival benefit for WT. Pediatr Blood Cancer.",
keywords = "FCDS, Neuroblastoma, Pediatric tumors, Volume-outcomes, Wilms tumor",
author = "Gutierrez, {Juan C.} and Cheung, {Michael C.} and Ying Zhuge and Koniaris, {Leonidas G.} and Sola, {Juan E}",
year = "2010",
month = "10",
day = "1",
doi = "10.1002/pbc.22631",
language = "English",
volume = "55",
pages = "621--628",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor?

AU - Gutierrez, Juan C.

AU - Cheung, Michael C.

AU - Zhuge, Ying

AU - Koniaris, Leonidas G.

AU - Sola, Juan E

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Purpose: To determine prognostic significance of hospital surgical volume and Children's Oncology Group (COG) membership on neuroblastoma (NBL) and Wilms tumor (WT) survival. Methods: The Florida Cancer Data System was queried from 1981 to 2004. Results: Of 869 NBL patients, 463 were treated at COG/HVC, 246 at COG/LVC, and 160 at non-COG/LVC. COG hospitals treated a larger proportion of patients <1 year of age (P = 0.002) and relatively more patients with adrenal and mediastinal tumors (P = 0.005). COG centers more frequently administered chemotherapy (72% vs. 51%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (70.6%, 67.7%) and COG/LVC (75.8%, 72.6%) than non-COG/LVC (59.5%, 54.4%, P < 0.05). Of 790 WT patients, 395 were treated at COG/HVC, 210 at COG/LVC, and 185 at non-COG/LVC. COG hospitals treated younger patients and lower staged tumors (P < 0.05). COG centers more frequently administered chemotherapy (88% vs. 59%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (91.3%, 89.9%) and COG/LVC (96.7%, 94.7%) than non-COG/LVC (82.4%, 81.7%, P < 0.05). Multivariate analysis demonstrated WT patients treated at non-COG hospitals, but not NBL patients, had worse survival (HR 3.107, P = 0.01). Conclusion: Children treated at COG hospitals had higher overall use of chemotherapy. This translated into a significantly improved survival benefit for WT. Pediatr Blood Cancer.

AB - Purpose: To determine prognostic significance of hospital surgical volume and Children's Oncology Group (COG) membership on neuroblastoma (NBL) and Wilms tumor (WT) survival. Methods: The Florida Cancer Data System was queried from 1981 to 2004. Results: Of 869 NBL patients, 463 were treated at COG/HVC, 246 at COG/LVC, and 160 at non-COG/LVC. COG hospitals treated a larger proportion of patients <1 year of age (P = 0.002) and relatively more patients with adrenal and mediastinal tumors (P = 0.005). COG centers more frequently administered chemotherapy (72% vs. 51%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (70.6%, 67.7%) and COG/LVC (75.8%, 72.6%) than non-COG/LVC (59.5%, 54.4%, P < 0.05). Of 790 WT patients, 395 were treated at COG/HVC, 210 at COG/LVC, and 185 at non-COG/LVC. COG hospitals treated younger patients and lower staged tumors (P < 0.05). COG centers more frequently administered chemotherapy (88% vs. 59%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (91.3%, 89.9%) and COG/LVC (96.7%, 94.7%) than non-COG/LVC (82.4%, 81.7%, P < 0.05). Multivariate analysis demonstrated WT patients treated at non-COG hospitals, but not NBL patients, had worse survival (HR 3.107, P = 0.01). Conclusion: Children treated at COG hospitals had higher overall use of chemotherapy. This translated into a significantly improved survival benefit for WT. Pediatr Blood Cancer.

KW - FCDS

KW - Neuroblastoma

KW - Pediatric tumors

KW - Volume-outcomes

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=77957061879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957061879&partnerID=8YFLogxK

U2 - 10.1002/pbc.22631

DO - 10.1002/pbc.22631

M3 - Article

C2 - 20806361

AN - SCOPUS:77957061879

VL - 55

SP - 621

EP - 628

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -